{
    "nctId": "NCT00169533",
    "briefTitle": "Rollover Study Of Lapatinib In Cancer Patients",
    "officialTitle": "An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NON_RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 31,
    "primaryOutcomeMeasure": "To determine the long-term safety and tolerability of lapatinib as monotherapy or in combination regimen",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Currently receiving clinical benefit as defined by CR, PR or SD from treatment with lapatinib through participation in a Phase I study of lapatinib either as monotherapy or as part of a combination regimen.\n* Ability to understand and provide written informed consent to participate in this trial.\n* Is male or female.\n* Female and male subjects agree to the protocol specific birth control measures\n\nExclusion Criteria:\n\n* Permanent discontinuation of lapatinib in the previous study due to intolerance or treatment failure.\n* Is a pregnant or lactating female.\n* Is considered medically unfit for the study by the investigator as a result of the medical interview, physical exam, or screening investigations.\n* Currently receiving treatment with any medications listed on the prohibited medication list (see Section 7.2).\n* Has Class III or IV heart failure as defined by the New York Heart Association (NYHA) functional classification system.\n* Has a left ventricular ejection fraction (LVEF) \\< 40% based on MUGA or ECHO.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}